Related Experiment Video
Updated: Feb 8, 2026

Generation of Native, Untagged Huntingtin Exon1 Monomer and Fibrils Using a SUMO Fusion Strategy
Published on: June 27, 2018
Calmidazolium Chloride and Its Complex with Serum Albumin Prevent Huntingtin Exon1 Aggregation
Virender Singh1, R N V Krishna Deepak2, Bhaswati Sengupta3
1Biological Sciences and Bioengineering , Indian Institute of Technology Kanpur , Kanpur 208016 , India.
Insights
Calmidazolium chloride inhibits Huntington's disease protein aggregation. A novel formulation using bovine serum albumin nanoparticles enhances this effect, reducing toxic polyglutamine aggregates in cells.
Area of Science:
- Neuroscience
- Genetics
- Biochemistry
Background:
- Huntington's disease (HD) is a fatal neurodegenerative disorder caused by a CAG repeat expansion in the Huntingtin gene.
- This expansion leads to a polyglutamine (polyQ) tract in the Huntingtin protein (Httex1), promoting toxic aggregate formation.
- Current treatments for HD are limited, highlighting the need for novel therapeutic strategies targeting protein aggregation.
Purpose of the Study:
- To investigate the potential of calmidazolium chloride (CLC) as an inhibitor of Httex1 aggregation.
- To develop a stabilized formulation of CLC to overcome its adsorption issues and enhance its inhibitory efficacy.
- To evaluate the therapeutic potential of CLC-loaded nanoparticles in reducing polyQ aggregates in HD models.
Main Methods:
- In vitro assessment of Httex1 aggregation inhibition by CLC.
- Development of a CLC-bovine serum albumin (BSA) complex to prevent CLC adsorption.
- Fabrication and characterization of biocompatible CLC-loaded BSA nanoparticles.
- Evaluation of nanoparticle efficacy in reducing polyQ aggregates in HD-150Q cells.
Main Results:
- Calmidazolium chloride demonstrated inhibitory effects on the initial aggregation steps of Httex1.
- The formation of a BSA-CLC complex successfully prevented CLC adsorption and improved Httex1 aggregation inhibition.
- BSA nanoparticles loaded with CLC effectively reduced polyglutamine aggregates in HD-150Q cells, indicating therapeutic potential.
Conclusions:
- Calmidazolium chloride is a promising agent for inhibiting Httex1 aggregation, a key process in Huntington's disease pathogenesis.
- BSA-based formulations, particularly nanoparticles, can enhance the stability and efficacy of CLC for potential therapeutic applications.
- CLC-loaded BSA nanoparticles represent a viable strategy for reducing toxic polyQ aggregates in Huntington's disease.
Abstract:
Huntington's disease (HD) is a genetic disorder caused by a CAG expansion mutation in Huntingtin gene leading to polyglutamine (polyQ) expansion in the N-terminus side of Huntingtin (Httex1) protein. Neurodegeneration in HD is linked to aggregates formed by Httex1 bearing an expanded polyQ. Initiation and elongation steps of Httex1 aggregation are potential target steps for the discovery of therapeutic molecules for HD, which is currently untreatable. Here we report Httex1 aggregation inhibition by calmidazolium chloride (CLC) by acting on the initial aggregation event. Because it is hydrophobic, CLC was adsorbed to the vial surface and could not sustain an inhibition effect for a longer duration. The use of bovine serum albumin (BSA) prevented CLC adsorption by forming a BSA-CLC complex. This complex showed improved Httex1 aggregation inhibition by interacting with the aggregation initiator, the NT17 part of Httex1. Furthermore, biocompatible CLC-loaded BSA nanoparticles were made which reduced the polyQ aggregates in HD-150Q cells.
Related Concept Videos
Protein Complex Assembly
Many viruses self-assemble into a fully functional unit using the infected host cell to...
Cancer Prevention
Some...
Formation of Complex Ions
Roles of Electrolytes: Chloride and Bicarbonate
Conditions such as hypochloremia can arise from insufficient chloride reabsorption by the kidneys, often compounded by extended bouts of diarrhea, vomiting,...
Carboxylic Acids to Acid Chlorides
Prevention of Further Absorption of Poison

